106 related articles for article (PubMed ID: 29394779)
21. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
[TBL] [Abstract][Full Text] [Related]
24. Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.
Fujiwara Y; Lee S; Kishida S; Hashiba R; Gyobu K; Naka R; Nishiyama M; Ihara T; Takemura M; Osugi H
Int J Clin Oncol; 2018 Oct; 23(5):877-885. PubMed ID: 29752605
[TBL] [Abstract][Full Text] [Related]
25. Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus.
Ui T; Fujii H; Hosoya Y; Nagase M; Mieno MN; Mori M; Zuiki T; Saito S; Kurashina K; Haruta H; Matsumoto S; Niki T; Lefor A; Yasuda Y
Dis Esophagus; 2015; 28(2):180-7. PubMed ID: 24529073
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study.
Umeki Y; Matsuoka H; Fujita M; Goto A; Serizawa A; Nakamura K; Akimoto S; Nakauchi M; Tanaka T; Shibasaki S; Inaba K; Uyama I; Suda K
Intern Med; 2023; 62(3):319-325. PubMed ID: 36725064
[TBL] [Abstract][Full Text] [Related]
27. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
[TBL] [Abstract][Full Text] [Related]
28. A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
Shimakawa T; Naritaka Y; Asaka S; Isohata N; Yamaguchi K; Murayama M; Konno S; Katsube T; Ogawa K; Ide H
Anticancer Res; 2010 Jan; 30(1):221-6. PubMed ID: 20150639
[TBL] [Abstract][Full Text] [Related]
29. Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
Matsuda S; Kitagawa Y; Takemura R; Okui J; Okamura A; Kawakubo H; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
Ann Surg; 2023 Jul; 278(1):e35-e42. PubMed ID: 35837977
[TBL] [Abstract][Full Text] [Related]
30. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Yamasaki M; Miyata H; Tanaka K; Shiraishi O; Motoori M; Peng YF; Yasuda T; Yano M; Shiozaki H; Mori M; Doki Y
Oncology; 2011; 80(5-6):307-13. PubMed ID: 21778771
[TBL] [Abstract][Full Text] [Related]
31. Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU).
Umeda M; Komatsubara H; Ojima Y; Minamikawa T; Shigeta T; Shibuya Y; Yokoo S; Komori T
Kobe J Med Sci; 2004; 50(5-6):189-96. PubMed ID: 16107776
[TBL] [Abstract][Full Text] [Related]
32. [Three cases of esophageal carcinoma achieved a pathological complete response after neoadjuvant chemotherapy with cisplatin and 5-fluorouracil].
Oyanagi H; Ichikawa H; Kosugi S; Banba T; Hanyu T; Hirashima K; Ishikawa T; Kameyama H; Kobayashi T; Minagawa M; Koyama Y; Wakai T
Gan To Kagaku Ryoho; 2015 Apr; 42(4):497-501. PubMed ID: 25963701
[TBL] [Abstract][Full Text] [Related]
33. Influence of preoperative docetaxel, cisplatin, and 5-fluorouracil on the incidence of complications after esophagectomy for resectable advanced esophageal cancer.
Yoshida N; Watanabe M; Baba Y; Ishimoto T; Iwagami S; Sakamoto Y; Miyamoto Y; Karashima R; Baba H
Dis Esophagus; 2014; 27(4):374-9. PubMed ID: 23927456
[TBL] [Abstract][Full Text] [Related]
34. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone.
Ancona E; Ruol A; Santi S; Merigliano S; Sileni VC; Koussis H; Zaninotto G; Bonavina L; Peracchia A
Cancer; 2001 Jun; 91(11):2165-74. PubMed ID: 11391598
[TBL] [Abstract][Full Text] [Related]
35. [Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
Katsumi C; Bamba T; Nakagawa S; Aizawa M; Matsuki A; Yabusaki H; Homma K
Gan To Kagaku Ryoho; 2017 Jan; 44(1):75-78. PubMed ID: 28174385
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study.
Pasini F; de Manzoni G; Zanoni A; Grandinetti A; Capirci C; Pavarana M; Tomezzoli A; Rubello D; Cordiano C
Cancer; 2013 Mar; 119(5):939-45. PubMed ID: 23165781
[TBL] [Abstract][Full Text] [Related]
37. Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
Shiraishi O; Kato H; Momose K; Hiraki Y; Yasuda A; Shinkai M; Imano M; Yasuda T
Oncology; 2023; 101(3):203-212. PubMed ID: 36599320
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma.
Takahashi T; Kaneoka Y; Maeda A; Takayama Y; Seita K
Updates Surg; 2022 Apr; 74(2):675-683. PubMed ID: 34559400
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
Osaka Y; Shinohara M; Hoshino S; Ogata T; Takagi Y; Tsuchida A; Aoki T
Anticancer Res; 2011 Feb; 31(2):633-8. PubMed ID: 21378349
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K
Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
